Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

GuruFocus.com11-08

Total Net Sales: $38.9 million, up 44% compared to Q3 2023. GAVRETO Net Product Sales: $7.1 million in its first full quarter. TAVALISSE Net Product Sales: $26.3 million, an 8% increase from Q3 2023. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481914211?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.V1Jseh.HnpHUqrxKDHePw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a17d0f037947c16326554b4b3a89ac26","is_english":true,"pubTime":"2024-11-08 15:27","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481914211","market":"us","top_or_hot":-1,"title":"Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...","media":"GuruFocus.com","content":"<div>\n<p>Total Net Sales: $38.9 million, up 44% compared to Q3 2023.\nGAVRETO Net Product Sales: $7.1 million in its first full quarter.\nTAVALISSE Net Product Sales: $26.3 million, an 8% increase from Q3 2023.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/rigel-pharmaceuticals-inc-rigl-q3-072727180.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 15:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/rigel-pharmaceuticals-inc-rigl-q3-072727180.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Net Sales: $38.9 million, up 44% compared to Q3 2023.\nGAVRETO Net Product Sales: $7.1 million in its first full quarter.\nTAVALISSE Net Product Sales: $26.3 million, an 8% increase from Q3 2023.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/rigel-pharmaceuticals-inc-rigl-q3-072727180.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RIGL","symbol_name":"Rigel Pharmaceuticals","start_time":0,"source_url":"https://finance.yahoo.com/news/rigel-pharmaceuticals-inc-rigl-q3-072727180.html","article_id":"2481914211","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.V1Jseh.HnpHUqrxKDHePw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a17d0f037947c16326554b4b3a89ac26"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481914211","pubTimestamp":1731050847,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total Net Sales: $38.9 million, up 44% compared to Q3 2023.GAVRETO Net Product Sales: $7.1 million in its first full quarter.TAVALISSE Net Product Sales: $26.3 million, an 8% increase from Q3 2023.REZLIDHIA Net Product Sales: $5.5 million, a 107% increase from Q3 2023.Contract Revenues from Collaborations: $16.4 million, including $13 million from Kissei.Net Income: $12.4 million, compared to a net loss of $5.7 million in Q3 2023.Cash, Cash Equivalents, and Short-term Investments: $61.1 million at the end of the quarter.GuruFocus has detected 6 Warning Signs with RIGL.Rigel Pharmaceuticals Inc  reported a 44% increase in net sales for the third quarter of 2024 compared to the same period in 2023, driven by strong performance across its commercial portfolio.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RIGL":"Rigel Pharmaceuticals"},"translate_title":"Rigel Pharmaceuticals Inc(RIGL)2024年第三季度收益看涨期权亮点：强劲的销售增长和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RIGL":1},"content_text":"Total Net Sales: $38.9 million, up 44% compared to Q3 2023.\nGAVRETO Net Product Sales: $7.1 million in its first full quarter.\nTAVALISSE Net Product Sales: $26.3 million, an 8% increase from Q3 2023.\nREZLIDHIA Net Product Sales: $5.5 million, a 107% increase from Q3 2023.\nContract Revenues from Collaborations: $16.4 million, including $13 million from Kissei.\nNet Income: $12.4 million, compared to a net loss of $5.7 million in Q3 2023.\nCash, Cash Equivalents, and Short-term Investments: $61.1 million at the end of the quarter.\n\n\nWarning! GuruFocus has detected 6 Warning Signs with RIGL.\n\nRelease Date: November 07, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nRigel Pharmaceuticals Inc (NASDAQ:RIGL) reported a 44% increase in net sales for the third quarter of 2024 compared to the same period in 2023, driven by strong performance across its commercial portfolio.\nThe addition of GAVRETO to Rigel's portfolio contributed $7.1 million in net product sales in its first full quarter, indicating successful integration and transition of patients and prescribers.\nRigel expanded its international presence through a new agreement with Kissei to develop and commercialize REZLIDHIA in Japan, Korea, and Taiwan, which included a $10 million upfront payment.\nThe company achieved positive net income for the third quarter and year-to-date, marking a significant financial milestone.\nRigel is advancing its pipeline with promising developments, including the R289 dual IRAK 1 and 4 inhibitor in a Phase 1b study, and strategic collaborations with MD Anderson and CONNECT to explore new cancer treatments.\n\n Negative Points \n\nDespite the positive sales growth, Rigel Pharmaceuticals Inc (NASDAQ:RIGL) faces challenges with some top centers not yet placing orders for GAVRETO, indicating potential logistical or market penetration issues.\nThe company reported a gross-to-net adjustment of 36% for TAVALISSE, which may impact overall profitability.\nThere are concerns about the safety profile of GAVRETO, with risks of severe and fatal infections due to off-target JAK1 and JAK2 inhibition, which could limit its uptake.\nRigel's cost of product sales increased, driven by higher sales, royalties, and amortization of intangible assets, which could pressure margins.\nThe competitive landscape for Rigel's products, such as the IRAK inhibitor space, remains challenging, with other companies exploring similar therapeutic areas.\n\n Q & A Highlights \nQ: Can you provide more color on TAVALISSE's balance between refills and new prescriptions? A: David Santos, Executive Vice President, Chief Commercial Officer: The majority of our business is carryover. Once patients start on TAVALISSE, they tend to stay on therapy, which contributes to our growth. New patient starts have also increased over the last couple of years, but the majority of growth is from existing patients continuing their treatment.\nQ: Regarding GAVRETO, several top centers have not placed orders. Is this due to logistics? A: David Santos, Executive Vice President, Chief Commercial Officer: A handful of top centers haven't placed direct orders, which we are investigating. However, 45% of our business was through the distribution channel to direct accounts in Q3, and this improved to 50% in October, aligning more with our expectations.\nQ: How should we think about the growth trajectory for GAVRETO, given its initial phase with Rigel? A: David Santos, Executive Vice President, Chief Commercial Officer: The majority of Q3 sales were true demand. We expect continued demand growth as more patients transition to our network. Dean Schorno, Chief Financial Officer, added that the majority of Q3 shipments were to patients and clinics, indicating strong demand.\nQ: For R289 in lower risk MDS, what is the bar for success in Phase 1b to advance the program? A: Lisa Rojkjaer, Executive Vice President, Chief Medical Officer: The study is unique as it includes relapsed/refractory patients. While first-line treatments show about 40% response rates, our study's inclusion criteria differ. We are encouraged by the preliminary safety and efficacy data thus far.\nQ: How might the new safety signal for GAVRETO affect its uptake, and does Retevmo have the same issue? A: Lisa Rojkjaer, Executive Vice President, Chief Medical Officer: The risk of infections is not new and is manageable by oncologists. The infections are primarily pneumonias, common in lung cancer patients. David Santos added that there have been no calls to their medical information line regarding this update, indicating no significant impact on GAVRETO's opportunity.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481914211"}